DOSIS 1/2022
Farmaseuttinen aikakauskirja DOSIS 4/2021 vol.37 5uomen Farmasialiitto ry
Farmaseuttinen aikakauskirja DOSIS 4/2021 vol.37 5uomen Farmasialiitto ry
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
This next part is about your attitude towards biosimilars.<br />
3. Which statement best describes what you understand a biosimilar to be?<br />
Please select one answer<br />
n A new biological<br />
n A generic biological<br />
n A counterfeit copy of a biological<br />
n A similar copy of a biological<br />
n I have heard about biosimilars, but I am not sure what they are<br />
n I have never heard about biosimilars<br />
4. For each of the following statement, please select<br />
one option which best describes your opinion.<br />
Strongly agree<br />
Agree<br />
Neither agree nor disagree<br />
Disagree<br />
Strongly disagree<br />
I am familiar with the term biosimilar<br />
I feel sufficiently informed about<br />
biosimilars<br />
I feel sufficiently informed to dispense<br />
biosimilars to patients<br />
I am confident in handling patient queries<br />
regarding their biologic therapy<br />
I am comfortable explaining the benefit<br />
and risk of biosimilars to patients<br />
I am comfortable with substituting<br />
an originator biological medicine<br />
with a biosimilar, in a situation where<br />
substitution at the pharmacy is permitted<br />
Suomen Farmasialiitto ry © 1/<strong>2022</strong> Vol. 38 Dosis 91
Change language